Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Matching mutations in tumours to precision medicine improves survival

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 768

Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA

Dr Tsimberidou presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show using molecular tests of tumours to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types.

She describes how, of the 1,307 patients with at least one genetic change in the cancer, the 3-year overall survival rate was 15% in the matched targeted group compared to 7% in the non-matched group.

The 10-year overall survival rate was 6% for the matched group and 1% in the non-matched group.

For more on these results, watch her interview with ecancer here, and read our news coverage here.

Slides from this presentation are available here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation